| Drug General Information |
| Drug ID |
D00MAM
|
| Former ID |
DIB012001
|
| Drug Name |
AMG-JAK2-01
|
| Synonyms |
JAK2 inhibitor (myeloproliferative disorder), Amgen
|
| Indication |
Myeloproliferative disorder [ICD10:C94.6]
|
Investigative |
[1]
|
|---|
| Company |
Amgen Inc
|
| Target and Pathway |
| Target(s) |
Tyrosine-protein kinase JAK2 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
Chemokine signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Jak-STAT signaling pathway
|
|
Cholinergic synapse
|
|
Prolactin signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Leishmaniasis
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Measles
|
|
Influenza A
|
|
Herpes simplex infection
|
|
PANTHER Pathway
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Interferon-gamma signaling pathway
|
|
JAK/STAT signaling pathway
|
|
PDGF signaling pathway
|
|
PI3 kinase pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Endothelins
|
|
ErbB4 signaling events
|
|
GMCSF-mediated signaling events
|
|
IL4-mediated signaling events
|
|
IL27-mediated signaling events
|
|
Signaling events mediated by PTP1B
|
|
IL12-mediated signaling events
|
|
S1P3 pathway
|
|
SHP2 signaling
|
|
CXCR4-mediated signaling events
|
|
IL5-mediated signaling events
|
|
IFN-gamma pathway
|
|
ErbB2/ErbB3 signaling events
|
|
IL3-mediated signaling events
|
|
IL6-mediated signaling events
|
|
PDGFR-beta signaling pathway
|
|
IL23-mediated signaling events
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
EPO signaling pathway
|
|
Notch-mediated HES/HEY network
|
|
Reactome
|
Interleukin-6 signaling
|
|
MAPK3 (ERK1) activation
|
|
MAPK1 (ERK2) activation
|
|
GPVI-mediated activation cascade
|
|
Prolactin receptor signaling
|
|
RMTs methylate histone arginines
|
|
G beta:gamma signalling through PI3Kgamma
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
RAF activation
|
|
RAF/MAP kinase cascade
|
|
Interferon gamma signaling
|
|
Regulation of IFNG signaling
|
|
Interleukin receptor SHC signaling
|
|
Growth hormone receptor signaling
|
|
Factors involved in megakaryocyte development and platelet production
|
|
WikiPathways
|
Serotonin Receptor 2 and STAT3 Signaling
|
|
Type II interferon signaling (IFNG)
|
|
Notch Signaling Pathway
|
|
EPO Receptor Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
IL-4 Signaling Pathway
|
|
IL-6 signaling pathway
|
|
Kit receptor signaling pathway
|
|
IL-3 Signaling Pathway
|
|
Mesodermal Commitment Pathway
|
|
Interleukin-2 signaling
|
|
Signaling by SCF-KIT
|
|
Prolactin receptor signaling
|
|
Growth hormone receptor signaling
|
|
JAK/STAT
|
|
BDNF signaling pathway
|
|
Oncostatin M Signaling Pathway
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
TSLP Signaling Pathway
|
|
IL17 signaling pathway
|
|
Leptin signaling pathway
|
|
TSH signaling pathway
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
Interferon gamma signaling
|
|
Factors involved in megakaryocyte development and platelet production
|
|
IL-5 Signaling Pathway
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048). |
|---|
